Abstract
Insomnia, an inability to initiate or maintain sleep, affects approximately one-third of the American population. Conventional benzodiazepines, such as triazolam and midazolam, were the treatment of choice for short-term insomnia for many years but are associated with adverse effects such as rebound insomnia, withdrawal and dependency. The newer hypnosedatives include zolpidem, zaleplon and zopiclone. These agents may be preferred over conventional benzodiazepines to treat short-term insomnia because they may be less likely to cause significant rebound insomnia or tolerance and are as efficacious as the conventional benzodiazepines. This review aims to summarise the published clinical drug interaction studies involving zolpidem, zaleplon and zopiclone. The pharmacokinetic and pharmacodynamic interactions that may be clinically important are highlighted.
Clinical trials have studied potential interactions of zaleplon, zolpidem and zopiclone with the following types of drugs: cytochrome P450 (CYP) inducers (rifampicin), CYP inhibitors (azoles, ritonavir and erythromycin), histamine H2 receptor antagonists (cimetidine and ranitidine), antidepressants, antipsychotics, antagonists of benzodiazepines and drugs causing sedation. Rifampicin significantly induced the metabolism of the newer hypnosedatives and decreased their sedative effects, indicating that a dose increase of these agents may be necessary when they are administered with rifampicin. Ketoconazole, erythromycin and cimetidine inhibited the metabolism of the newer hypnosedatives and enhanced their sedative effects, suggesting that a dose reduction may be required. Addition of ethanol to treatment with the newer hypnosedatives resulted in additive sedative effects without altering the pharmacokinetic parameters of the drugs.
Compared with some of the conventional benzodiazepines, fewer clinically important interactions appear to have been reported in the literature with zaleplon, zolpidem and zopiclone. The fact that these drugs are newer to the market and have not been as extensively studied as the conventional benzodiazepines may be the reason for this. Another explanation may be a difference in CYP metabolism. While triazolam and midazolam are biotransformed almost entirely via CYP3A4, the newer hypnosedatives are biotransformed by several CYP isozymes in addition to CYP3A4, resulting in CYP3A4 inhibitors and inducers having a lesser effect on their biotransformation.
Similar content being viewed by others
References
Benca RM. Sleep in psychiatric disorders. Neurol Clin 1996; 14(4): 739–64
Kupfer DJ, Reynolds CF. Management of insomnia. N Engl J Med 1997; 336(5): 341–6
Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother 1998; 32(6): 680–91
Davies M, Newell JG, Derry JM, et al. Characterization of the interaction of zopiclone with gamma-aminobutyric acid type A receptors. Mol Pharmacol 2000; 58(4): 756–62
Dooley M, Plosker GL. Zaleplon: a review of its use in the treatment of insomnia. Drugs 2000; 60(2): 413–45
Langer SZ, Arbilla S. Limitations of the benzodiazepine receptor nomenclature: a proposal for a pharmacological classification as omega receptor subtypes. Fundam Clin Pharmacol 1988; 2(3): 159–70
Langer SZ, Arbilla S, Tan S, et al. Selectivity for omega-receptor subtypes as a strategy for the development of anxiolytic drugs. Pharmacopsychiatry 1990; 23Suppl. 3: 103–7
Sanger DJ, Benavides J, Perrault G, et al. Recent developments in the behavioral pharmacology of benzodiazepine (omega) receptors: evidence for the functional significance of receptor subtypes. Neurosci Biobehav Rev 1994; 18(3): 355–72
Langtry HD, Benfield P. Zolpidem: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1990; 40(2): 291–313
Concas A, Serra M, Santoro G, et al. The effect of cyclopyrrolones on GABAA receptor function is different from that of benzodiazepines. Naunyn Schmiedebergs Arch Pharmacol 1994; 350(3): 294–300
Villikka K, Kivistö KT, Luurila H, et al. Rifampin reduces plasma concentrations and effects of zolpidem. Clin Pharmacol Ther 1997; 62(6): 629–34
Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. Clin Pharmacol Ther 1998; 64(6): 661–71
Luurila H, Kivistö KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. Eur J Clin Pharmacol 1998; 54(2): 163–6
Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr 2000; 24(2): 129–36
Hulhoven R, Desager JP, Harvengt C, et al. Lack of interaction between zolpidem and H2 antagonists, cimetidine and ranitidine. Int J Clin Pharmacol Res 1988; 8(6): 471–6
Piergies AA, Sweet J, Johnson M, et al. The effect of co-administration of zolpidem with fluoxetine: pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 1996; 34(4): 178–83
Allard S, Sainati S, Roth-Schechter B, et al. Minimal interaction between fluoxetine and multiple-dose zolpidem in healthy women. Drug Metab Dispos 1998; 26(7): 617–22
Allard S, Sainati S, Roth-Schechter B. Coadministration of short-term zolpidem with sertraline in healthy women. J Clin Pharmacol 1999; 39: 184–91
Harvengt C, Hulhoven R, Desager JP, et al. Drug interactions investigated with zolpidem. In: Sauvanet JP, Langer SZ, Morselli PL, editors. Imidazopyridines in sleep disorders. New York: Raven Press, 1988: 165–73
Desager JP, Hulhoven R, Harvengt C, et al. Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic. Psychopharmacology (Berl) 1988; 96(1): 63–6
Patat A, Naef MM, van Gessel E, et al. Flumazenil antagonizes the central effects of zolpidem, an imidazopyridine hypnotic. Clin Pharmacol Ther 1994; 56(4): 430–6
Wilkinson CJ. The acute effects of zolpidem, administered alone and with alcohol, on cognitive and psychomotor function. J Clin Psychiatry 1995; 56(7): 309–18
Mattila MJ, Nurminen ML, Vainio P, et al. Zolpidem 10mg given at daytime is not antagonized by 300mg caffeine in man. Eur J Clin Pharmacol 1998; 54(5): 421–5
Hetta J, Broman JE, Darwish M, et al. Psychomotor effects of zaleplon and thioridazine coadministration. Eur J Clin Pharmacol 2000; 56(3): 211–7
Sanchez Garcia P, Carcas A, Zapater P, et al. Absence of an interaction between ibuprofen and zaleplon. Am J Health Syst Pharm 2000; 57(12): 1137–41
Roehrs T, Rosenthal L, Koshorek G, et al. Effects of zaleplon or triazolam with or without ethanol on human performance. Sleep Med 2001; 2(4): 323–32
Villikka K, Kivistö KT, Lamberg TS, et al. Concentrations and effects of zopiclone are greatly reduced by rifampicin. Br J Clin Pharmacol 1997; 43(5): 471–4
Jalava KM, Olkkola KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. Eur J Clin Pharmacol 1996; 51(3–4): 331–4
Aranko K, Luurila H, Backman JT, et al. The effect of erythromycin on the pharmacokinetics and pharmacodynamics of zopiclone. Br J Clin Pharmacol 1994; 38(4): 363–7
Mattila MJ, Vanakoski J, Mattila-Evenden ME, et al. Suriclone enhances the actions of chlorpromazine on human psychomotor performance but not on memory or plasma prolactin in healthy subjects. Eur J Clin Pharmacol 1994; 46(3): 215–20
Wilson CM, Robinson FP, Thompson EM, et al. Effect of pretreatment with ranitidine on the hypnotic action of single doses of midazolam, temazepam and zopiclone: a clinical study. Br J Anaesth 1986; 58(5): 483–6
Mattila ME, Mattila MJ, Nuotto E. Caffeine moderately antagonizes the effects of triazolam and zopiclone on the psychomotor performance of healthy subjects. Pharmacol Toxicol 1992; 70(4): 286–9
Saano V, Hansen PP, Paronen P. Interactions and comparative effects of zopiclone, diazepam and lorazepam on psychomotor performance and on elimination pharmacokinetics in healthy volunteers. Pharmacol Toxicol 1992; 70(2): 135–9
Kuitunen T, Mattila MJ, Seppälä T. Actions and interactions of hypnotics on human performance: single doses of zopiclone, triazolam and alcohol. Int Clin Psychopharmacol 1990; 5Suppl. 2: 115–30
Caille G, du Souich P, Spenard J, et al. Pharmacokinetic and clinical parameters of zopiclone and trimipramine when administered simultaneously to volunteers. Biopharm Drug Dispos 1984; 5(2): 117–25
Seppälä T, Nuotto E, Dreyfus JF. Drug-alcohol interactions on psychomotor skills: zopiclone and flunitrazepam. Pharmacology 1983; 27Suppl. 2: 127–35
Neylan TC. Treatment of sleep disturbances in depressed patients. J Clin Psychiatry 1995; 56Suppl. 2: 56–61
Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 2000; 59(4): 865–89
Greenblatt DJ, Harmatz JS, von Moltke LL, et al. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin Pharmacol Ther 1998; 64(5): 553–61
Salva P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem: therapeutic implications. Clin Pharmacokinet 1995; 29(3): 142–53
Von Moltke LL, Greenblatt DJ, Granda BW, et al. Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. Br J Clin Pharmacol 1999; 48(1): 89–97
Pichard L, Gillet G, Bonfils C, et al. Oxidative metabolism of zolpidem by human liver cytochrome P450S. Drug Metab Dispos 1995; 23(11): 1253–62
Toner LC, Tsambiras BM, Catalano G, et al. Central nervous system side effects associated with zolpidem treatment. Clin Neuropharmacol 2000; 23(1): 54–8
Ware JC, Walsh JK, Scharf MB, et al. Minimal rebound insomnia after treatment with 10-mg zolpidem. Clin Neuropharmacol 1997; 20(2): 116–25
Renwick AB, Mistry H, Ball SE, et al. Metabolism of zaleplon by human hepatic microsomal cytochrome P450 isoforms. Xenobiotica 1998; 28(4): 337–48
Fernandez C, Maradeix V, Gimenez F, et al. Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. Drug Metab Dispos 1993; 21(6): 1125–8
Chouinard G, Lefko-Singh K, Teboul E. Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zopiclone, and zolpidem. Cell Mol Neurobiol 1999; 19(4): 533–52
Gaillot J, Heusse D, Hougton GW, et al. Pharmacokinetics and metabolism of zopiclone. Pharmacology 1983; 27Suppl. 2: 76–91
Goa KL, Heel RC. Zopiclone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. Drugs 1986; 32(1): 48–65
Noble S, Langtry HD, Lamb HM. Zopiclone: an update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia. Drugs 1998; 55(2): 277–302
Gaillot J, Le Roux Y, Houghton GW, et al. Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. Sleep 1987; 10Suppl. 1: 7–21
Becquemont L, Mouajjah S, Escaffre O, et al. Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. Drug Metab Dispos 1999; 27(9): 1068–73
Venkatesan K. Pharmacokinetic drug interactions with rifampicin. Clin Pharmacokinet 1992; 22(1): 47–65
Rae JM, Johnson MD, Lippman ME, et al. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 2001; 299(3): 849–57
Rodriguez-Antona C, Jover R, Gomez-Lechon MJ, et al. Quantitative RT-PCR measurement of human cytochrome P-450s: application to drug induction studies. Arch Biochem Biophys 2000; 376(1): 109–16
Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996; 59(1): 7–13
Villikka K, Kivistö KT, Backman JT, et al. Triazolam is ineffective in patients taking rifampin. Clin Pharmacol Ther 1997; 61(1): 8–14
Ohnhaus EE, Brockmeyer N, Dylewicz P, et al. The effect of antipyrine and rifampin on the metabolism of diazepam. Clin Pharmacol Ther 1987; 42(2): 148–56
Ochs HR, Greenblatt DJ, Roberts GM, et al. Diazepam interaction with antituberculosis drugs. Clin Pharmacol Ther 1981; 29(5): 671–8
Brockmeyer NH, Mertins L, Klimek K, et al. Comparative effects of rifampin and/or probenecid on the pharmacokinetics of temazepam and nitrazepam. Int J Clin Pharmacol Ther Toxicol 1990; 28(9): 387–93
Backman JT, Olkkola KT, Ojala M, et al. Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 1996; 37(3): 253–7
Scott AK, Khir AS, Steele WH, et al. Oxazepam pharmacokinetics in patients with epilepsy treated long-term with phenytoin alone or in combination with phenobarbitone. Br J Clin Pharmacol 1983; 16(4): 441–4
Moore LB, Goodwin B, Jones SA, et al. St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 2000; 97(13): 7500–2
Wang Z, Gorski JC, Hamman MA, et al. The effects of St John’s wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001; 70(4): 317–26
Darwish M. Overview of drug-interaction studies with zaleplon [abstract]. Sleep 1999; 22: S280
Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 56(6 Pt 1): 601–7
von Moltke LL, Greenblatt DJ, Harmatz JS, et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996; 276(2): 370–9
Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 55(5): 481–5
Greenblatt DJ, Wright CE, von Moltke LL, et al. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. Clin Pharmacol Ther 1998; 64(3): 237–47
Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clin Pharmacol Ther 1998; 64(3): 278–85
Phillips JP, Antal EJ, Smith RB. A pharmacokinetic drug interaction between erythromycin and triazolam. J Clin Psychopharmacol 1986; 6(5): 297–9
Olkkola KT, Aranko K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993; 53(3): 298–305
Yeates RA, Laufen H, Zimmermann T. Interaction between midazolam and clarithromycin: comparison with azithromycin. Int J Clin Pharmacol Ther 1996; 34(9): 400–5
Luurila H, Olkkola KT, Neuvonen PJ. Lack of interaction of erythromycin with temazepam. Ther Drug Monit 1994; 16(6): 548–51
Ahonen J, Olkkola KT, Neuvonen PJ. Lack of effect of antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam. Ther Drug Monit 1996; 18(2): 124–7
Sparber A, Wootton JC, Bauer L, et al. Use of complementary medicine by adult patients participating in HIV/AIDS clinical trials. J Altern Complement Med 2000; 6(5): 415–22
Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38(1): 41–57
Kanamitsu S, Ito K, Green CE, et al. Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm Res 2000; 17(4): 419–26
Weber FH, Richards RD, McCallum RW. Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am J Gastroenterol 1993; 88(4): 485–90
Hansten PD. Drug interactions with antisecretory agents. Aliment Pharmacol Ther 1991; 5Suppl. 1: 121–8
Martinez C, Albet C, Agundez JA, et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther 1999; 65(4): 369–76
Powell JR, Rogers JF, Wargin WA, et al. Inhibition of theophylline clearance by cimetidine but not ranitidine. Arch Intern Med 1984; 144(3): 484–6
Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther 1999; 13Suppl. 3: 18–26
Russell RM, Golner BB, Krasinski SD, et al. Effect of antacid and H2 receptor antagonists on the intestinal absorption of folic acid. J Lab Clin Med 1988; 112(4): 458–63
Schmidt EK, Antonin KH, Flesch G, et al. An interaction study with cimetidine and the new angiotensin II antagonist valsartan. Eur J Clin Pharmacol 1998; 53(6): 451–8
Fee JP, Collier PS, Howard PJ, et al. Cimetidine and ranitidine increase midazolam bioavailability. Clin Pharmacol Ther 1987; 41(1): 80–4
Sanders LD, Whitehead C, Gildersleve CD, et al. Interaction of H2-receptor antagonists and benzodiazepine sedation: a double-blind placebo-controlled investigation of the effects of cimetidine and ranitidine on recovery after intravenous midazolam. Anaesthesia 1993; 48(4): 286–92
Ochs HR, Greenblatt DJ, Friedman H, et al. Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. Clin Pharmacol Ther 1987; 41(5): 562–70
Friedman H, Greenblatt DJ, Burstein ES, et al. Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. J Clin Pharmacol 1988; 28(3): 228–33
Abernethy DR, Greenblatt DJ, Divoll M, et al. Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. Psychopharmacology (Berl) 1983; 80(3): 275–8
Klotz U, Reimann I. Elevation of steady-state diazepam levels by cimetidine. Clin Pharmacol Ther 1981; 30(4): 513–7
Abernethy DR, Greenblatt DJ, Divoll M, et al. Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. J Pharmacol Exp Ther 1983; 224(3): 508–13
Greenblatt DJ, Abernethy DR, Divoll M, et al. Noninteraction of temazepam and cimetidine. J Pharm Sci 1984; 73(3): 399–401
Klotz U, Reimann I. Influence of cimetidine on the pharmacokinetics of desmethyldiazepam and oxazepam. Eur J Clin Pharmacol 1980; 18(6): 517–20
Grimsley SR, Jann MW. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm 1992; 11(11): 930–57
Rascati K. Drug utilization review of concomitant use of specific serotonin reuptake inhibitors or clomipramine with antianxiety/sleep medications. Clin Ther 1995; 17(4): 786–90
Ruther E. Depression, circadian rhythms and trimipramine. Drugs 1989; 38Suppl. 1: 1–3
Ware JC. Tricyclic antidepressants in the treatment of insomnia. J Clin Psychiatry 1983; 44(9 Pt 2): 25–8
Haria M, Fitton A, McTavish D. Trazodone: a review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging 1994; 4(4): 331–55
Boerner RJ, Moller HJ. The importance of new antidepressants in the treatment of anxiety/depressive disorders. Pharmacopsychiatry 1999; 32(4): 119–26
Kast RE. Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy. Support Care Cancer 2001; 9(6): 469–70
Scates AC, Doraiswamy PM. Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression. Ann Pharmacother 2000; 34(11): 1302–12
Greenblatt DJ, Preskorn SH, Cotreau MM, et al. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992; 52(5): 479–86
Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 1994; 46(1): 35–9
Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 2002; 3(1): 13–37
Wright CE, Lasher-Sisson TA, Steenwyk RC, et al. A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine. Pharmacotherapy 1992; 12(2): 103–6
Preskorn SH, Alderman J, Greenblatt DJ, et al. Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo. Psychopharmacol Bull 1997; 33(4): 659–65
Preskorn SH, Greenblatt DJ, Harvey AT. Lack of effect of sertraline on the pharmacokinetics of alprazolam. J Clin Psychopharmacol 2000; 20(5): 585–6
Stark P, Hardison CD. A review of multicenter controlled studies of fluoxetine vs imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry 1985; 46(3 Pt 2): 53–8
Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32Suppl. 1: 1–21
Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions. J Clin Psychopharmacol 1999; 19(5): 23S–35S
Liston HL, DeVane CL, Boulton DW, et al. Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. J Clin Psychopharmacol 2002; 22(2): 169–73
Cone AM, Stott SA. Flumazenil. Br J Hosp Med 1994; 51(7): 346–8
Mattila MJ, Nuotto E. Caffeine and theophylline counteract diazepam effects in man. Med Biol 1983; 61(6): 337–43
Mattila MJ, Vainio P, Nurminen ML, et al. Midazolam 12mg is moderately counteracted by 250mg caffeine in man. Int J Clin Pharmacol Ther 2000; 38(12): 581–7
Lariviere L, Caille G, Elie R. The effects of low and moderate doses of alcohol on the pharmacokinetic parameters of zopiclone. Biopharm Drug Dispos 1986; 7(2): 207–10
Delcker A, Wilhelm H, Timmann D, et al. Side effects from increased doses of carbamazepine on neuropsychological and posturographic parameters of humans. Eur Neuropsychopharmacol 1997; 7(3): 213–8
Kuitunen T, Mattila MJ, Seppälä T, et al. Actions of zopiclone and carbamazepine, alone and in combination, on human skilled performance in laboratory and clinical tests. Br J Clin Pharmacol 1990; 30(3): 453–61
Sanchez Garcia P, Paty I, Leister CA, et al. Effect of zaleplon on digoxin pharmacokinetics and pharmacodynamics. Am J Health Syst Pharm 2000; 57(24): 2267–70
Darwish M. Analysis of potential drug interactions with zaleplon [abstract]. J Am Geriatr Soc 1999; 47: S62
Greenblatt DJ, Shader RI. Effects of age and other drugs on benzodiazepine kinetics. Arzneimittel Forschung 1980; 30(5a): 886–90
Ono S, Hatanaka T, Miyazawa S, et al. Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica 1996; 26(11): 1155–66
Acknowledgements
The authors were supported by the following grants from the National Institutes of Health, US Department of Health and Human Services: MH-58435, DA-13209, DA-13834, DK-58496, DA-05258, RR-00054. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hesse, L.M., von Moltke, L.L. & Greenblatt, D.J. Clinically Important Drug Interactions with Zopiclone, Zolpidem and Zaleplon. CNS Drugs 17, 513–532 (2003). https://doi.org/10.2165/00023210-200317070-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00023210-200317070-00004